Press Releases

All Releases
View Summary Five Prime Therapeutics and Bristol-Myers Squibb Sign Collaboration Agreement to Discover Novel Immuno-Oncology Therapies for Two Immune Checkpoint Pathways
Monday, March 17, 2014
PDF 19.8 KB Add to Briefcase
View Summary Five Prime Therapeutics to Present at 26th Annual Roth Conference
Wednesday, March 5, 2014
PDF 7.0 KB Add to Briefcase
View Summary Five Prime Therapeutics Announces Closing of Public Offering
Wednesday, February 12, 2014
PDF 7.2 KB Add to Briefcase
View Summary Five Prime Announces the Full Exercise of the Underwriters' Option to Purchase Additional Shares
Monday, February 10, 2014
PDF 7.3 KB Add to Briefcase
View Summary Five Prime Therapeutics Prices Public Offering of Common Stock
Thursday, February 6, 2014
PDF 6.6 KB Add to Briefcase
View Summary Five Prime Therapeutics to Present at BIO CEO
Monday, February 3, 2014
PDF 15.6 KB Add to Briefcase
View Summary Five Prime Therapeutics Enters Into Antibody Research Collaboration Agreement With Adimab
Thursday, January 9, 2014
PDF 8.2 KB Add to Briefcase
View Summary Five Prime Therapeutics to Present at Piper Jaffray Healthcare Conference
Wednesday, November 20, 2013
PDF 6.0 KB Add to Briefcase
View Summary Five Prime Therapeutics Announces Third Quarter 2013 Financial Results
Tuesday, November 12, 2013
PDF 15.9 KB Add to Briefcase
View Summary ADC Therapeutics Licenses Proprietary Antibodies From Five Prime Therapeutics, Adds an Additional Proprietary ADC Development Program in Oncology
Tuesday, November 5, 2013
PDF 10.2 KB Add to Briefcase
View Summary Five Prime Therapeutics Doses First Cohort of Subjects in Phase 1 Study of FPA008
Thursday, October 31, 2013
PDF 10.0 KB Add to Briefcase
View Summary Five Prime Therapeutics to Announce Third Quarter 2013 Financial Results and Host Conference Call on November 12
Tuesday, October 29, 2013
PDF 6.1 KB Add to Briefcase
View Summary Five Prime Therapeutics Appoints Aron Knickerbocker to Its Board of Directors and Marc Belsky to Chief Financial Officer
Wednesday, October 23, 2013
PDF 8.6 KB Add to Briefcase
View Summary Five Prime Announces the Exercise of the Underwriters' Over-Allotment Option
Thursday, September 26, 2013
PDF 16.6 KB Add to Briefcase
View Summary Five Prime Therapeutics Announces Closing of Initial Public Offering
Monday, September 23, 2013
PDF 16.6 KB Add to Briefcase
View Summary Five Prime Therapeutics Announces Pricing of Initial Public Offering
Tuesday, September 17, 2013
PDF 17.0 KB Add to Briefcase
View Summary UCB AND FIVE PRIME THERAPEUTICS ANNOUNCE STRATEGIC DISCOVERY COLLABORATION
Tuesday, March 19, 2013
PDF 7.1 KB Add to Briefcase
View Summary FIVE PRIME THERAPEUTICS ANNOUNCES ADDITION OF JULIE HAMBLETON, M.D., AS SENIOR VICE PRESIDENT AND CHIEF MEDICAL OFFICER
Monday, December 3, 2012
PDF 7.7 KB Add to Briefcase
View Summary Lonza and Biowa Sign License Agreements with FivePrime Therapeutics for Use of Their POTELLIGENT® CHOK1SV Cell Line for Therapeutic Antibody Development
Wednesday, June 13, 2012
PDF 12.7 KB Add to Briefcase
View Summary Five Prime Therapeutics Announces that Human Genome Sciences Files U.S. IND for HGS1036/FP-1039 FGF Ligand Trap
Monday, June 4, 2012
PDF 7.0 KB Add to Briefcase
Showing 141-160 of 191 Page: 1 ... 4 5 6 7 8 9 10  Previous 20 | Next 20
Add to Briefcase = add release to Briefcase

FPRX (Common Stock)

Exchange
NASDAQ
Price
25.56
Change (%)
-0.20
Volume
409,193

Data as of 4:00 PM ET on Friday, November 17, 2017
Minimum 20 minute delay
Refresh quote
Powered By eSignal, Inc.